Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

SA Transcripts158.67K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST Company Participants Sharon Klahre - Vice President of Investor Relations & CommunicationsMichael Metzger - CEO & DirectorSteven Closter - Chief Commercial OfficerNicholas Botwood - Head of Research & Development and Chief Medical OfficerKeith Goldan - CFO, Treasurer & Chief Accounting Officer Conference Call Participants Priyanka Grover - JPMorgan Chase & Co, Research DivisionCorinne Jenkins - Goldman Sachs Group, Inc., Research DivisionYuxi Dong - Jefferies LLC, Research DivisionJoseph BowenPhilip Nadeau - TD Cowen, Research DivisionStephen Willey - Stifel, Nicolaus & Company, Incorporated, Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research DivisionEtzer Darout - Barclays Bank PLC, Research DivisionXiaochuan Dai - UBS Investment Bank, Research DivisionYigal Nochomovitz - Citigroup Inc., Research DivisionSalim Syed - Mizuho Securities USA LLC, Research DivisionJason Zemansky - BofA Securities, Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. [Operator Instructions]. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals. Sharon KlahreVice President of Investor Relations & Communications Thank you, Operator. Welcome, and thank you all for joining us today for a review of Syndax's Fourth Quarter and Full Year 2025 Financial and Operating Results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steve Closter, Chief Commercial Officer; Dr. Nick Botwood, Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on Slide 2. Before we